Listing of Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Previously Presented) A compound of formula I:



I

wherein A is



,

R^3, R^4, R^5 and R^6 are each, independently, H, halogen, NO_2,

C_{1-10}- alkyl, optionally substituted by halogen up to perhaloalkyl,

C_{1-10}-alkoxy, optionally substituted by halogen up to perhaloalkoxy,

C_{1-10}- alkanoyl, optionally substituted by halogen up to perhaloalkanoyl,

C_{6-12} aryl, optionally substituted by C_{1-10} alkyl or C_{1-10} alkoxy, or

C_{5-12} hetaryl, optionally substituted by C_{1-10} alkyl or C_{1-10} alkoxy,

and either

one of R^3, R^4, and R^5 is –M-L^1; or

two adjacent of R^3, R^4, R^5 and R^6 together are an aryl or hetaryl ring with 5-12 atoms, optionally substituted by C_{1-10}-alkyl, , halo-substituted C_{1-10}-alkyl up to perhaloalkyl, C_{1-10}-alkoxy, halo-substituted C_{1-10}-alkoxy up to perhaloalkoxy, C_{3-10}-cycloalkyl, C_{2-10}-alkenyl, C_{1-10}-alkanoyl, C_{6-12}-aryl, C_{5-12}-hetaryl; C_{6-12}-aralkyl, C_{6-12}-alkaryl, halogen; NR^1R^1; $-NO_2$; $-CF_3$; $-COOR^1$; $-NHCOR^1$; -CN; $-CONR^1R^1$; $-SO_2R^2$; $-SOR^2$; $-SR^2$;

in which

R^1 is H or C_{1-10}-alkyl, optionally substituted by halogen up to perhaloalkyl and

R^2 is C_{1-10}-alkyl, optionally substituted by halogen, up to perhaloalkyl,

$R^{3'}$, $R^{4'}$, $R^{5'}$ and $R^{6'}$ are independently H, halogen,

C_1 - C_{10} alkyl, optionally substituted by halogen up to perhaloalkyl,

C_1 –C_{10} alkoxy optionally substituted by halogen up to perhaloalkoxy or two adjacent of $R^{3'}$, $R^{4'}$, $R^{5'}$ and $R^{6'}$, together with the base phenyl, form a naphthyl group, optionally substituted by halogen up to perhalo, C_{1-10} alkyl, C_{1-10} alkoxy, C_{3-10} cycloalkyl, C_{2-10} alkenyl, C_{1-10} alkanoyl, C_{6-12} aryl, C_{5-12} hetaryl or C_{6-12} aralkyl;

M is $–CH_2$-, -S-, $-N(CH_3)$-, -NHC(O)- $-CH_2$-S-, $-S-CH_2$-, -C(O)-, or –O-; and

L^1 is phenyl, substituted by C_{1-10}-alkoxy, OH, $-SCH_3$, or by

pyridyl, optionally substituted by C_{1-10}-alkyl, C_{1-10}-alkoxy, halogen, OH, $-SCH_3$, or NO_2,

naphthyl, optionally substituted by C_{1-10}-alkyl, C_{1-10}-alkoxy, halogen, OH, $-SCH_3$ or NO_2,

pyridone, optionally substituted by C_{1-10}-alkyl, C_{1-10}-alkoxy, halogen, OH, $-SCH_3$ or NO_2,

pyrazine, optionally substituted by C_{1-10}-alkyl, C_{1-10}-alkoxy, halogen, OH, $-SCH_3$ or NO_2,

pyrimidine, optionally substituted by C_{1-10}-alkyl, C_{1-10}-alkoxy, halogen, OH, $-SCH_3$ or NO_2,

benzodioxane, optionally substituted by C_{1-10}-alkyl, C_{1-10}-alkoxy, halogen, OH, $-SCH_3$ or NO_2,

benzopyridine, optionally substituted by C_{1-10}-alkyl, one C_{1-10}-alkoxy, halogen, -OH, $-SCH_3$ or NO_2 ,

or

benzothiazole, optionally substituted by, C_{1-10} alkyl C_{1-10} alkoxy, halogen, OH, $-SCH_3$ or NO_2, and wherein the compound of formula I has a pKa greater than 10,

or a pharmaceutically acceptable salt thereof.

2. (Cancelled)

3. (Previously Presented) A compound according to claim 1, wherein

R^3 is H, halogen or C_{1-10}- alkyl, optionally substituted by halogen, up to perhaloalkyl;

R^4 is H, halogen or NO_2;

R^5 is H, halogen or C_{1-10}- alkyl;

R^6 is H, C_{1-10}- alkoxy, thiophene, pyrole or methyl substituted pyrole,

$R^{3'}$ is H, halogen, C_{4-10}-alkyl, or CF_3 and

$R^{6'}$ is H, halogen, CH_3, CF_3 or $-OCH_3$.

4. **(Previously Presented)** A compound according to claim 1, wherein

$R^{3'}$ is C_{4-10}-alkyl, Cl, F or CF_3;

$R^{4'}$ is H, Cl or F ;

$R^{5'}$ is H, Cl, F or C_{4-10}-alkyl; and

$R^{6'}$ is H or OCH_3.

5. **(Previously Presented)** A compound according to claim 4, wherein $R^{3'}$ or $R^{5'}$ is t-butyl.

6. **(Previously Presented)** A compound according to claim 1, wherein M is $-CH_2-$, $-N(CH_3)-$ or $-NHC(O)-$.

7. **(Previously Presented)** A compound according to claim 6, wherein L^1 is phenyl or pyridyl.

8. **(Previously Presented)** A compound according to claim 1, wherein M is –O-.

9. **(Previously Presented)** A compound according to claim 8, wherein L^1 is phenyl, pyridyl, pyridone or benzothiazole.

10. **(Previously Presented)** A compound according to claim 1, wherein M is –S-.

11. **(Previously Presented)** A compound according to claim 10, wherein L^1 is phenyl or pyridyl.

12. **(Previously Presented)** A compound of the formula



.

13. **(Original)** A pharmaceutical composition comprising a compound of claim 1, and a physiologically acceptable carrier.

14. **(Original)** A pharmaceutical composition comprising a compound of claim 12, and a physiologically acceptable carrier.

15. **(Cancelled)**

16. (Previously Presented) A method for the treatment of a cancerous cell growth mediated by raf kinase, comprising administering a compound of formula IIa:



IIa

wherein A is



,

R^3, R^4, R^5 and R^6 are each independently H, halogen, NO_2,

C_{1-10}- alkyl, optionally substituted by halogen up to perhaloalkyl,

C_{1-10}-alkoxy, optionally substituted by halogen up to perhaloalkoxy,

C_{1-10}- alkanoyl, optionally substituted by halogen up to perhaloalkanoyl,

C_{6-12} aryl, optionally substituted by C_{1-10} alkyl or C_{1-10} alkoxy, or

C_{5-12} hetaryl, optionally substituted by C_{1-10} alkyl or C_{1-10} alkoxy,

and either

one of R^3, R^4, R^5 and R^6 is $-M-L^1$; or

two adjacent of R^3, R^4, R^5 and R^6 together are an aryl or hetaryl ring with 5-12 atoms, optionally substituted by C_{1-10}-alkyl, halo-substituted C_{1-10}-alkyl up to perhaloalkyl, C_{1-10}-alkoxy, halo-substituted C_{1-10}-alkoxy up to perhaloalkoxy, C_{3-10}-cycloalkyl, C_{2-10}-alkenyl, C_{1-10}-alkanoyl; C_{6-12}-aryl, C_{5-12}-hetaryl, C_{6-12}-alkaryl, halogen; $-NR^1R^1$; $-NO_2$; $-CF_3$;-$COOR^1$; -$NHCOR^1$; -CN; -$CONR^1R^1$; -SO_2R^2; -SOR^2; -SR^2;

in which

R^1 is H or C_{1-10}-alkyl, optionally substituted by halogen, up to perhalo and

R^2 is C_{1-10}-alkyl, optionally substituted by halogen,

$R^{3'}$, $R^{4'}$, $R^{5'}$ and $R^{6'}$ are independently H, halogen, C_1 - C_{10} alkyl, optionally substituted by halogen up to perhaloalkyl, C_1 –C_{10} alkoxy optionally substituted by halogen up to perhaloalkoxy or two adjacent of $R^{3'}$, $R^{4'}$, $R^{5'}$ and $R^{6'}$, together with the base phenyl, form a naphthyl group optionally substituted by halogen up to perhalo, C_{1-10} alkyl, C_{1-10} alkoxy, C_{3-10} cycloalkyl, C_{2-10} alkenyl, C_{1-10} alkanoyl, C_{6-12} aryl, C_{5-12} hetaryl or C_{6-12} aralkyl, halogen up to perhalo;

M is –CH_2-, -S-, -$N(CH_3)$-, -NHC(O)- -CH_2-S-, -S-CH_2-, -C(O)-, or –O-; and

L^1 is phenyl, pyridyl, naphthyl, pyridone, pyrazine, pyrimidine, benzodiaxane, benzopyridine or benzothiazole, each optionally substituted by C_{1-10}-alkyl, C_{1-10}-alkoxy, halogen, OH, -SCH_3, NO_2 or, where Y is phenyl, by



or a pharmaceutically acceptable salt thereof.

17. (Previously Presented) A method according to claim 16, wherein

R^3 is halogen or C_{1-10}- alkyl, optionally substituted by halogen, up to perhaloalkyl;

R^4 is H, halogen or NO_2;

R^5 is H, halogen or C_{1-10}- alkyl;

R^6 is H , C_{1-10}- alkoxy, thiophene, pyrole or methylsubstituted pyrole

$R^{3'}$ is H, halogen, C_{4-10}-alkyl, or CF_3 and

$R^{6'}$ is H, halogen, CH_3 , CF_3 or OCH_3.

18. (Previously Presented) A method according to claim 16, wherein M is $-CH_2-$,–S-, $-N(CH_3)-$ or –NHC(O)- and L^1 is phenyl or pyridyl.

19. (Previously Presented) A method according to claim 16, wherein M is –O- and L^1 is phenyl, pyridone, pyrimidine, pyridyl or benzothiazole.

20. (Cancelled)

21. (Previously Presented) A compound of formula I:



I

wherein A is



,

wherein

R^3 is H, halogen or C_{1-10}- alkyl, optionally substituted by halogen, up to perhaloalkyl;

R^4 is H, halogen or NO_2;

R^5 is H, halogen or C_{1-10}- alkyl;

R^6 is H, C_{1-10}- alkoxy, thiophene, pyrole or methyl substituted pyrole,

$R^{3'}$ is H, Cl, F, C_{4-10}-alkyl, or CF_3 and

$R^{4'}$ is H, Cl or F ;

$R^{5'}$ is H, Cl, F or C_{4-10}-alkyl; and

$R^{6'}$ is H, halogen, CH_3, CF_3 or $-OCH_3$,.

and one of R^3, R^4, and R^5 is $-M-L^1$; wherein

M is $-CH_2$-, -S-, $-N(CH_3)$-, -NHC(O)- $-CH_2$-S-, -S-CH_2-, -C(O)-, or –O-; and

L^1 is phenyl, substituted by C_{1-10}-alkoxy, OH, $-SCH_3$, or by

pyridyl, optionally substituted by C_{1-10}-alkyl, C_{1-10}-alkoxy, halogen, OH, $-SCH_3$, or NO_2,

naphthyl, optionally substituted by C_{1-10}-alkyl, C_{1-10}-alkoxy, halogen, OH, $-SCH_3$ or NO_2,

pyridone, optionally substituted by C_{1-10}-alkyl, C_{1-10}-alkoxy, halogen, OH, $-SCH_3$ or NO_2,

pyrazine, optionally substituted by C_{1-10}-alkyl, C_{1-10}-alkoxy, halogen, OH, $-SCH_3$ or NO_2,

pyrimidine, optionally substituted by C_{1-10}-alkyl, C_{1-10}-alkoxy, halogen, OH, $-SCH_3$ or NO_2,

benzodioxane, optionally substituted by C_{1-10}-alkyl, C_{1-10}-alkoxy, halogen, OH, $-SCH_3$ or NO_2,

benzopyridine, optionally substituted by C_{1-10}-alkyl, one C_{1-10}-alkoxy, halogen, $-SCH_3$ or NO_2 ,

or

benzothiazole, optionally substituted by, C_{1-10} alkyl C_{1-10} alkoxy, halogen, $-SCH_3$ or NO_2, and wherein the compound of formula I has a pKa greater than 10,

or a pharmaceutically acceptable salt thereof.

22. (Previously Presented) A compound according to claim 21, wherein $R^{3'}$ or $R^{5'}$ is t-butyl.

23. (Previously Presented) A compound according to claim 21, wherein M is $-CH_2-$, $-N(CH_3)-$ or $-NHC(O)-$.

24. (Previously Presented) A compound according to claim 21, wherein L^1 is phenyl or pyridyl.

25. (Previously Presented) A compound according to claim 21, wherein M is –S-.

26. (Previously Presented) A compound according to claim 25, wherein L^1 is phenyl or pyridyl.

27. (Previously Presented) A compound of formula I:



I

wherein A is



,

R^3, R^4, R^5 and R^6 are each, independently, H, halogen, NO_2,

C_{1-10}- alkyl, optionally substituted by halogen up to perhaloalkyl,

C_{1-10}-alkoxy, optionally substituted by halogen up to perhaloalkoxy,

C_{1-10}- alkanoyl, optionally substituted by halogen up to perhaloalkanoyl,

C_{6-12} aryl, optionally substituted by C_{1-10} alkyl or C_{1-10} alkoxy, or

C_{5-12} hetaryl, optionally substituted by C_{1-10} alkyl or C_{1-10} alkoxy,

and either

one of R^3, R^4, and R^5 is –M-L^1; or

two adjacent of R^3, R^4, R^5 and R^6 together are an aryl or hetaryl ring with 5-12 atoms, optionally substituted by C_{1-10}-alkyl, , halo-substituted C_{1-10}-alkyl up to perhaloalkyl, C_{1-10}-alkoxy, halo-substituted C_{1-10}-alkoxy up to perhaloalkoxy, C_{3-10}-cycloalkyl, C_{2-10}-alkenyl, C_{1-10}-alkanoyl, C_{6-12}-aryl, C_{5-12}-hetaryl; C_{6-12}-aralkyl, C_{6-12}-alkaryl, halogen; NR^1R^1; $-NO_2$; $-CF_3$; -$COOR^1$; -$NHCOR^1$; -CN; -$CONR^1R^1$; -SO_2R^2; -SOR^2; -SR^2;

in which

R^1 is H or C_{1-10}-alkyl, optionally substituted by halogen up to perhaloalkyl and R^2 is C_{1-10}-alkyl, optionally substituted by halogen, up to perhaloalkyl,

$R^{3'}$, $R^{4'}$, $R^{5'}$ and $R^{6'}$ are independently H, halogen,

C_1 - C_{10} alkyl, optionally substituted by halogen up to perhaloalkyl,

C_1 –C_{10} alkoxy optionally substituted by halogen up to perhaloalkoxy or two adjacent of $R^{3'}$, $R^{4'}$, $R^{5'}$ and $R^{6'}$, together with the base phenyl, form a naphthyl group, optionally substituted by halogen up to perhalo, $C_{1\text{-}10}$ alkyl, $C_{1\text{-}10}$ alkoxy, $C_{3\text{-}10}$ cycloalkyl, $C_{2\text{-}10}$ alkenyl, $C_{1\text{-}10}$ alkanoyl, $C_{6\text{-}12}$ aryl, $C_{5\text{-}12}$ hetaryl or $C_{6\text{-}12}$ aralkyl;

M is –CH_2-, -S-, -$N(CH_3)$-, -NHC(O)- -CH_2-S-, -S-CH_2-, -C(O)-, or –O-; and

L^1 is phenyl, substituted by $C_{1\text{-}10}$-alkoxy, OH, -SCH_3, or by

pyridyl, optionally substituted by $C_{1\text{-}10}$-alkyl, $C_{1\text{-}10}$-alkoxy, halogen, OH, -SCH_3 , or NO_2,

naphthyl, optionally substituted by $C_{1\text{-}10}$-alkyl, $C_{1\text{-}10}$-alkoxy, halogen, OH, -SCH_3 or NO_2,

pyridone, optionally substituted by $C_{1\text{-}10}$-alkyl, $C_{1\text{-}10}$-alkoxy, halogen, OH, -SCH_3 or NO_2,

pyrazine, optionally substituted by $C_{1\text{-}10}$-alkyl, $C_{1\text{-}10}$-alkoxy, halogen, OH, -SCH_3 or NO_2,

pyrimidine, optionally substituted by $C_{1\text{-}10}$-alkyl, $C_{1\text{-}10}$-alkoxy, halogen, OH, -SCH_3 or NO_2,

benzodioxane, optionally substituted by $C_{1\text{-}10}$-alkyl, $C_{1\text{-}10}$-alkoxy, halogen, OH, -SCH_3 or NO_2,

benzopyridine, optionally substituted by $C_{1\text{-}10}$-alkyl, one $C_{1\text{-}10}$-alkoxy, halogen, OH, -SCH_3 or NO_2 ,

or

benzothiazole, optionally substituted by, $C_{1\text{-}10}$ alkyl $C_{1\text{-}10}$ alkoxy, halogen, OH, -SCH_3 or NO_2, or a pharmaceutically acceptable salt thereof.

28. (Previously Presented) A method according to claim 16, wherein lung carcinoma is treated.

29. (Previously Presented) A method according to claim 16, wherein pancreas carcinoma is treated.

30. (Previously Presented) A method according to claim 16, wherein thyroid carcinoma is treated.

31. (Previously Presented) A method according to claim 16, wherein bladder carcinoma is treated.

32. (Previously Presented) A method according to claim 16, wherein colon carcinoma is treated.

33. (Previously Presented) A method according to claim 16, wherein myeloid leukemia is treated.

34. (Previously Presented) A compound according to claim 27, wherein

L^1 is phenyl, substituted by C_{1-10}-alkoxy, $-SCH_3$, or by

pyridyl, optionally substituted by C_{1-10}-alkyl, C_{1-10}-alkoxy, halogen, $-SCH_3$, or NO_2,

naphthyl, optionally substituted by C_{1-10}-alkyl, C_{1-10}-alkoxy, halogen, $-SCH_3$ or NO_2,

pyridone, optionally substituted by C_{1-10}-alkyl, C_{1-10}-alkoxy, halogen, $-SCH_3$ or NO_2,

pyrazine, optionally substituted by C_{1-10}-alkyl, C_{1-10}-alkoxy, halogen, $-SCH_3$ or NO_2,

pyrimidine, optionally substituted by C_{1-10}-alkyl, C_{1-10}-alkoxy, halogen, $-SCH_3$ or NO_2,

benzodioxane, optionally substituted by C_{1-10}-alkyl, C_{1-10}-alkoxy, halogen, $-SCH_3$ or NO_2,

benzopyridine, optionally substituted by C_{1-10}-alkyl, one C_{1-10}-alkoxy, halogen, $-SCH_3$ or NO_2,

or

benzothiazole, optionally substituted by, C_{1-10} alkyl C_{1-10} alkoxy, halogen, $-SCH_3$ or NO_2.

35. (New) A method for the treatment of a cancerous cell growth mediated by raf kinase, comprising administering a compound of formula II:



II

or a pharmaceutically acceptable salt thereof wherein

A is



B is a substituted or unsubstituted, up to bicyclic aryl or heteroaryl moiety of up to 12 carbon atoms with at least one 6-member aromatic structure containing 0-4 members of the group consisting of nitrogen, oxygen and sulfur, wherein if B is substituted it is substituted by one or more substituents selected from the group consisting of halogen, up to per-halo, and W_n, wherein n is 0-3 and each W is independently selected from the group consisting of –CN, $-CO_2R^7$, $-C(O)NR^7R^7$, $-C(O)-R^7$, $-NO_2$, $-OR^7$, $-SR^7$, $-NR^7R^7$, $-NR^7C(O)OR^7$, $-NR^7C(O)R^7$, C_1-C_{10} alkyl, C_2-C_{10} alkenyl, C_1-C_{10} alkenoyl,C_1-C_{10} alkoxy, C_3-C_{10} cycloalkyl, C_6-C_{14} aryl, optionally substituted with halogen, C_1-C_{10} alkyl, or C_1-C_{10} alkoxy; C_7-C_{24} alkaryl, optionally substituted with halogen, C_1-C_{10} alkyl, or C_1-C_{10} alkoxy; C_3-C_{13} heteroaryl, optionally substituted with halogen, C_1-C_{10} alkyl, or C_1-C_{10} alkoxy; C_4-C_{23} alkheteroaryl, optionally substituted with halogen, C_1-C_{10} alkyl, or C_1-C_{10} alkoxy; substituted C_1-C_{10} alkyl, substituted C_2-C_{10} alkenyl, substituted C_2-C_{10} alkenoyl, substituted C_1-C_{10} alkoxy, substituted C_3-C_{10} cycloalkyl, substituted C_4-C_{23} alkheteroaryl and –M-L^1;

wherein if W is a substituted group which does not contain aryl or hetaryl moieties, it is substituted by one or more substituents independently selected from the group consisting of –CN, $-CO_2R^7$, $-C(O)R^7$, $-C(O)NR^7R^7$, $-OR^7$, $-SR^7$, $-NR^7R^7$, NO_2, $-NR^7C(O)R^7$, $-NR^7C(O)OR^7$ and halogen up to per-halo;

wherein each R^7 is independently selected from H, C_1-C_{10} alkyl, C_2-C_{10} alkenyl, C_3-C_{10} cycloalkyl, C_6-C_{14} aryl, C_3-C_{13} hetaryl, C_7-C_{24} alkaryl, C_4-C_{23} alkheteroaryl, up to per-halosubstituted C_1-C_{10} alkyl, up to per-halo substituted C_2-C_{10} alkenyl, up to per-halosubstituted C_3-C_{10} cycloalkyl, up to per-halosubstituted C_6-C_{14} aryl and up to per-halosubstituted C_3-C_{13} hetaryl,

wherein M is - O-, -S-, $-N(R^7)$-, $-(CH_2)_m$-, -C(O)-, -CH(OH)-, $-(CH_2)_mO$-,

$-NR^7C(O)\ NR^7R^7$-, $-NR^7C(O)$-, $-C(O)NR^7$-, $-(CH_2)_mS$-, $-(CH_2)_mN(R^7)$-, $-O(CH_2)_m$-, $-CHX^a$, $-CX^a_2$-, -S-$(CH_2)_m$- and $-N(R^7)(CH_2)_m$-,

m = 1-3, and X^a is halogen; and

L^1 is a 5-10 member aromatic structure containing 0-2 members of the group consisting of nitrogen, oxygen and sulfur, which is unsubstituted or substituted by halogen up to per-halo and optionally substituted by Z_{n1}, wherein $_{n1}$ is 0 to 3 and each Z is independently selected from the group consisting of –CN, $-CO_2R^7$, $-C(O)NR^7R^7$, -C(O)- NR^7, $-NO_2$, $-OR^7$, - SR^7, - NR^7R^7, $-NR^7C(O)OR^7$, $-C(O)R^7$, $-NR^7C(O)R^7$, C_1-C_{10} alkyl, C_3-C_{10} cycloalkyl, C_6-C_{14} aryl, C_3-C_{13} hetaryl, C_7-C_{24} alkaryl, C_4-C_{23} alkheteroaryl, substituted C_1-C_{10} alkyl, substituted C_3-C_{10} cycloalkyl, substituted C_7-C_{24} alkaryl and substituted C_4-C_{23} alkheteroaryl; wherein the one or more substituents of Z is selected from the group consisting of –CN, $-CO_2R^7$, $-C(O)NR^7R^7$, $-OR^7$, $-SR^7$, $-NO_2$, $-NR^7R^7$, $-NR^7C(O)R^7$ and $-NR^7C(O)OR^7$,

wherein $R^{3'}$, $R^{4'}$, $R^{5'}$ and $R^{6'}$ are each independently H, halogen, C_{1-10}-alkyl, optionally substituted by halogen up to perhaloalkyl, C_1 –C_{10} alkoxy, optionally substituted by halogen up to perhaloalkoxy or two adjacent of $R^{3'}$, $R^{4'}$, $R^{5'}$ and $R^{6'}$ together with the base phenyl, form a naphthyl group, optionally substituted by halogen up to perhalo, C_{1-10} alkyl, C_{1-10} alkoxy, C_{3-10} cycloalkyl, C_{2-10} alkenyl, C_{1-10} alkanoyl, C_{6-12} aryl, C_{5-12} hetaryl or C_{6-12} aralkyl.

36. (New) A compound of formula I, which is in crystalline form or in a solvated form:



I

wherein A is



,

R^3, R^4, R^5 and R^6 are each, independently, H, halogen, NO_2,

C_{1-10}- alkyl, optionally substituted by halogen up to perhaloalkyl,

C_{1-10}-alkoxy, optionally substituted by halogen up to perhaloalkoxy,

C_{1-10}- alkanoyl, optionally substituted by halogen up to perhaloalkanoyl,

C_{6-12} aryl, optionally substituted by C_{1-10} alkyl or C_{1-10} alkoxy, or

C_{5-12} hetaryl, optionally substituted by C_{1-10} alkyl or C_{1-10} alkoxy,

and either

one of R^3, R^4, and R^5 is –M-L^1; or

two adjacent of R^3, R^4, R^5 and R^6 together are an aryl or hetaryl ring with 5-12 atoms, optionally substituted by C_{1-10}-alkyl, , halo-substituted C_{1-10}-alkyl up to perhaloalkyl, C_{1-10}-alkoxy, halo-substituted C_{1-10}-alkoxy up to perhaloalkoxy, C_{3-10}-cycloalkyl, C_{2-10}-alkenyl, C_{1-10}-alkanoyl, C_{6-12}-aryl, C_{5-12}-hetaryl; C_{6-12}-aralkyl, C_{6-12}-alkaryl, halogen; NR^1R^1; $-NO_2$; $-CF_3$; -$COOR^1$; -$NHCOR^1$; -CN; -$CONR^1R^1$; -SO_2R^2; -SOR^2; -SR^2;

in which

R^1 is H or C_{1-10}-alkyl, optionally substituted by halogen up to perhaloalkyl and

R^2 is C_{1-10}-alkyl, optionally substituted by halogen, up to perhaloalkyl,

$R^{3'}$, $R^{4'}$, $R^{5'}$ and $R^{6'}$ are independently H, halogen,

C_1 - C_{10} alkyl, optionally substituted by halogen up to perhaloalkyl,

C_1 –C_{10} alkoxy optionally substituted by halogen up to perhaloalkoxy or two adjacent of $R^{3'}$, $R^{4'}$, $R^{5'}$ and $R^{6'}$, together with the base phenyl, form a naphthyl group, optionally substituted by halogen up to perhalo, $C_{1\text{-}10}$ alkyl, $C_{1\text{-}10}$ alkoxy, $C_{3\text{-}10}$ cycloalkyl, $C_{2\text{-}10}$ alkenyl, $C_{1\text{-}10}$ alkanoyl, $C_{6\text{-}12}$ aryl, $C_{5\text{-}12}$ hetaryl or $C_{6\text{-}12}$ aralkyl;

M is –CH_2-, -S-, -$N(CH_3)$-, -NHC(O)- -CH_2-S-, -S-CH_2-, -C(O)-, or –O-; and

L^1 is phenyl, substituted by $C_{1\text{-}10}$-alkoxy, OH, -SCH_3, or by

pyridyl, optionally substituted by $C_{1\text{-}10}$-alkyl, $C_{1\text{-}10}$-alkoxy, halogen, OH, -SCH_3 , or NO_2,

naphthyl, optionally substituted by $C_{1\text{-}10}$-alkyl, $C_{1\text{-}10}$-alkoxy, halogen, OH, -SCH_3 or NO_2,

pyridone, optionally substituted by $C_{1\text{-}10}$-alkyl, $C_{1\text{-}10}$-alkoxy, halogen, OH, -SCH_3 or NO_2,

pyrazine, optionally substituted by $C_{1\text{-}10}$-alkyl, $C_{1\text{-}10}$-alkoxy, halogen, OH, -SCH_3 or NO_2,

pyrimidine, optionally substituted by $C_{1\text{-}10}$-alkyl, $C_{1\text{-}10}$-alkoxy, halogen, OH, -SCH_3 or NO_2,

benzodioxane, optionally substituted by $C_{1\text{-}10}$-alkyl, $C_{1\text{-}10}$-alkoxy, halogen, OH, -SCH_3 or NO_2,

benzopyridine, optionally substituted by $C_{1\text{-}10}$-alkyl, one $C_{1\text{-}10}$-alkoxy, halogen, -OH, -SCH_3 or NO_2 ,

or

benzothiazole, optionally substituted by, $C_{1\text{-}10}$ alkyl $C_{1\text{-}10}$ alkoxy, halogen, OH, -SCH_3 or NO_2, and wherein the compound of formula I has a pKa greater than 10,

or a pharmaceutically acceptable salt thereof.

37. **(New)** A compound according to claim 1, which has an IC_{50} value of between 1 nM and 10 μM in an *in vitro* raf kinase assay.

38. **(New)** A method for treating cancer comprising administering a compound according to claim 36 to a subject in need thereof in an effective amount, which compound is in crystalline form.

39. **(New)** A method for treating cancer comprising administering a compound according to claim 36 to a subject in need thereof in an effective amount, which compound is in solvated form.